159309-66-7

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Pyridinol,2-amino-6-chloro-(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and functional groups allow for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 3-Pyridinol,2-amino-6-chloro-(9CI) serves as a crucial component in the production of pesticides and other crop protection agents. Its incorporation into these products enhances their effectiveness in controlling pests and diseases.
Used in Organic Chemistry Research:
3-Pyridinol,2-amino-6-chloro-(9CI) is utilized as a versatile reagent in organic chemistry research. Its ability to participate in various chemical reactions, such as nucleophilic substitution and electrophilic aromatic substitution, makes it a valuable tool for the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Pyridinol,2-amino-6-chloro-(9CI) is employed as a building block for the development of novel therapeutic agents. Its unique structural features and reactivity contribute to the design and synthesis of new compounds with potential medicinal properties.
It is important to handle 3-Pyridinol,2-amino-6-chloro-(9CI) with care, as it may have potential risks and hazards associated with its use. Proper safety measures should be taken during its handling and application to minimize any potential risks.

Upstream product

• 887471-39-8 6-chloro-2-nitropyridin-3-ol 
• 41288-96-4 6-chloropyridine-3-ol 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL)

The application relates to heterocyclic compounds of the general formula (I), compositions comprising such compounds, a process for preparing these compounds and their medical use. The compounds act as monoacylglycerol lipase (MAGL) inhibitors and are useful in the treatment of neuroinflammation, neurodegenerative diseases, pain, cancer or mental disorders.

Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies

Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were designed and synthesized based on hits identified from Aurigene's compound library. The advanced lead compound, CA-4948, demonstrated good cellular activity in ABC DLBCL and AML cell lines. Inhibition of TLR signaling leading to decreased IL-6 levels was also observed in whole blood assays. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation. CA-4948 was well tolerated in toxicity studies in both mouse and dog at efficacious exposure. The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia.

SUBSTITUTED AZA COMPOUNDS AS IRAK-4 INHIBITORS

The present invention provides substituted aza compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.

BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein A, Y, Z, X1, X2, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, 'm', 'n' and 'p' have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.